Financial News
Articles published by Cellectis Inc.
![](https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png)
![](https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png)
![](https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png)
![](https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png)
![](https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png)
![](https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png)
Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023
May 11, 2023
From Cellectis Inc.
Via GlobeNewswire
Tickers
CLLS
![](https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png)
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2023
May 04, 2023
From Cellectis Inc.
Via GlobeNewswire
Tickers
CLLS
![](https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png)
![](https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png)
![](https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png)
Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab
April 24, 2023
From Cellectis Inc.
Via GlobeNewswire
Tickers
CLLS
![](https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png)
![](https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png)
![](https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png)
![](https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png)
![](https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png)
Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
March 08, 2023
From Cellectis Inc.
Via GlobeNewswire
Tickers
CLLS
![](https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png)
![](https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png)
Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023
March 01, 2023
From Cellectis Inc.
Via GlobeNewswire
Tickers
CLLS
![](https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png)
Cellectis Announces Closing of Global Offering and Exercise of Underwriters’ Option to Purchase Additional Shares
February 07, 2023
From Cellectis Inc.
Via GlobeNewswire
Tickers
CLLS
![](https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png)
Cellectis Supplements the Announcement of the Pricing of Follow-On Offering with Allocation of Share Capital Information
February 03, 2023
From Cellectis Inc.
Via GlobeNewswire
Tickers
CLLS
![](https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png)
Cellectis Announces Pricing of Follow-On Offering
February 03, 2023
From Cellectis Inc.
Via GlobeNewswire
Tickers
CLLS
![](https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png)
Cellectis Announces Launch of Follow-On Offering
February 02, 2023
From Cellectis Inc.
Via GlobeNewswire
Tickers
CLLS
![](https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png)
Cellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics
January 20, 2023
From Cellectis Inc.
Via GlobeNewswire
Tickers
CLLS
![](https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png)
From Cellectis Inc.
Via GlobeNewswire
![](https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png)
![](https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png)
![](https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png)
![](https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png)
Cellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML
December 13, 2022
From Cellectis Inc.
Via GlobeNewswire
Tickers
CLLS
![](https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png)
Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022
December 01, 2022
From Cellectis Inc.
Via GlobeNewswire
Tickers
CLLS
![](https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.